The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy

被引:115
作者
Beauregard, Jean-Mathieu [1 ,2 ,3 ,4 ]
Hofman, Michael S. [3 ,4 ]
Kong, Grace [3 ,4 ]
Hicks, Rodney J. [3 ,4 ]
机构
[1] CHU Quebec, Mol Imaging Res Grp, Dept Med Imaging, Quebec City, PQ G1R 3S2, Canada
[2] Univ Laval, Quebec City, PQ G1R 3S2, Canada
[3] Peter MacCallum Canc Ctr, Ctr Canc Imaging, Melbourne, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
关键词
Ga-68-DOTA-octreotate; Biodistribution; Dosimetry; Neuroendocrine tumour; Peptide receptor radionuclide therapy; PET/CT; Somatostatin receptor; RENAL TOXICITY; BODY-SURFACE; DOSIMETRY; GA-68;
D O I
10.1007/s00259-011-1937-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Tumour sequestration of radiotracer may lead to decreased bioavailability in healthy tissue resulting in lower absorbed radiation dose to critical organs. This study aims to assess the impact of disease burden, body habitus and urinary excretion on the biodistribution of Ga-68-DOTA-octreotate. Methods Ten patients with highly varied burden of somatostatin receptor-positive neuroendocrine tumour on Ga-68-DOTA-octreotate positron emission tomography (PET)/CT were selected. Volumes of interest were drawn to derive the average uptake of renal parenchyma, spleen and body background, as well as to compute the fraction of injected activity sequestered in tumour and excreted in urine. Uptake values were assessed for correlation with tumour sequestration, weight, lean body weight, body surface area and urinary excretion. Results There was a trend for tumour sequestration, body habitus and urinary excretion to inversely influence all healthy tissue uptake values. In particular, renal uptake, splenic intensity and background soft tissue activity were all significantly correlated to composite factors combining tumour sequestration with body habitus and renal excretion. When combined with body habitus index or a body habitus index and renal excretion, tumour sequestration was strongly and significantly correlated inversely with renal uptake. Conclusion Our results suggest that tumour sequestration of Ga-68-DOTA-octreotate is a major factor leading to a sink effect that decreases activity concentration in healthy organs such as the kidney. However, body habitus and renal function also influence tissue biodistribution, in a synergistic fashion. Compared with a fixed-dose peptide receptor radionuclide therapy protocol, an adjusted-dose regimen tailored to tumour burden, body habitus and renal function may allow greater radiation dose to individual lesions without substantially adding to toxicity in normal tissues.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 20 条
  • [1] Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
    Beauregard, Jean-Mathieu
    Hofman, Michael S.
    Pereira, Jucilene M.
    Eu, Peter
    Hicks, Rodney J.
    [J]. CANCER IMAGING, 2011, 11 (01) : 56 - 66
  • [2] Beauregard JM, 2009, J NUCL MED, V50, pS1657
  • [3] Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
    Bodei, Lisa
    Cremonesi, Marta
    Ferrari, Mahila
    Pacifici, Monica
    Grana, Chiara M.
    Bartolomei, Mirco
    Baio, Silvia M.
    Sansovini, Maddalena
    Paganelli, Giovanni
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1847 - 1856
  • [4] 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax
    Boy, Christian
    Heusner, Till A.
    Poeppel, Thorsten D.
    Redmann-Bischofs, Anja
    Unger, Nicole
    Jentzen, Walter
    Brandau, Wolfgang
    Mann, Klaus
    Antoch, Gerald
    Bockisch, Andreas
    Petersenn, Stephan
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (07) : 1224 - 1236
  • [5] BREEMAN WAP, 1995, J NUCL MED, V36, P623
  • [6] Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours:: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide
    Förster, GJ
    Engelbach, M
    Brockmann, J
    Reber, H
    Buchholz, HG
    Mäcke, HR
    Rösch, F
    Herzog, H
    Bartenstein, P
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (12) : 1743 - 1750
  • [7] SHOULD CLEARANCE BE NORMALIZED TO BODY-SURFACE OR TO LEAN BODY-MASS
    HALLYNCK, TH
    SOEP, HH
    THOMIS, JA
    BOELAERT, J
    DANEELS, R
    DETTLI, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (05) : 523 - 526
  • [8] 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
    Hubble, Daniel
    Kong, Grace
    Michael, Michael
    Johnson, Val
    Ramdave, Shakher
    Hicks, Rodney John
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (10) : 1869 - 1875
  • [9] Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours
    Kaemmerer, Daniel
    Peter, Luisa
    Lupp, Amelie
    Schulz, Stefan
    Saenger, Joerg
    Prasad, Vikas
    Kulkarni, Harshad
    Haugvik, Sven-Petter
    Hommann, Merten
    Baum, Richard Paul
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (09) : 1659 - 1668
  • [10] Metabolic Super Scan in 18F-FDG PET/CT Imaging
    Kim, Dae-Weung
    Kim, Chang Guhn
    Park, Soon-Ah
    Jung, Sang-Ah
    Yang, Sei-Hoon
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (08) : 1256 - 1257